Contrast material-enhanced visualization of the ablation medium for magnetic resonance-monitored ethanol injection therapy: Imaging and safety aspects

Journal of Vascular and Interventional Radiology

Volumn 17, Issue 1, 2006, Pages 95-102

  Nanz, Daniel ^a   Andreisek, Gustav ^a   Fröhlich, Johannes M ^a   Weishaupt, Dominik ^a   Treiber, Karl ^a   Ess, Sonja ^a   Pfammatter, Thomas ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CONTRAST MEDIUM; GADOLINIUM; GADOTERATE MEGLUMINE; WATER; DIAGNOSTIC AGENT; MEGLUMINE; ORGANOMETALLIC COMPOUND; PROTON;

ARTICLE; DISSOCIATION; IMAGE ANALYSIS; IMAGE DISPLAY; IN VITRO STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR SAFETY; PRIORITY JOURNAL; STORAGE; TEMPERATURE; ARTERIOVENOUS MALFORMATION; CHEMISTRY; HUMAN; IMAGE ENHANCEMENT; INTRALESIONAL DRUG ADMINISTRATION; METHODOLOGY; SOLUBILITY; TIME;

ARTERIOVENOUS MALFORMATIONS; CONTRAST MEDIA; ETHANOL; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; INJECTIONS, INTRALESIONAL; MAGNETIC RESONANCE IMAGING; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PROTONS; SOLUBILITY; TIME FACTORS; WATER;

EID: 33745303554     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000187100.19700.DD     Document Type: Article

References (40)

1. Garcea G, Lloyd TD, Aylott C, et al. The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumors. Eur J Cancer 2003; 39:2150-2164.
2. Shibata T, Yamamoto Y, Yamamoto N, et al. Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. J Vasc Interv Radiol 2003; 14:1535-1542.
3. Etlik O, Arslan H, Bay A, et al. Abdominal hydatid disease: long-term results of percutaneous treatment. Acta Radiol 2004; 45:383-389.
4. Puig S, Aref H, Brunelle F. Double-needle sclerotherapy of lymphangiomas and venous angiomas in children. AJR Am J Roentgenol 2003; 180:1399-1401.
5. Guglielmi R, Pacella CM, Bianchini A, et al. Percutaneous ethanol injection treatment in benign thyroid lesions: role and efficacy. Thyroid 2004; 14:125-131.
6. Plante MK, Folsom JB, Zvara P. Prostatic tissue ablation by injection: a literature review. J Urol 2004; 172:20-26.
7. Nielsen CD, Spencer WHI. Role of controlled septal infarct in hypertrophic obstructive cardiomyopathy. Cardiol Rev 2002; 10:108-118.
8. Kovacic JC, Muller DWM. Hypertrophic cardiomyopathy: state-of-the-art review, with focus on the management of outflow obstruction. Intern Med J 2003; 33:521-529.
9. Burrows PE, Mason KP. Percutaneous treatment of low flow vascular malformations. J Vasc Interv Radiol 2004; 15:431-445.
10. Goyal M, Causer PA, Armstrong D. Venous vascular malformations in pediatric patients: comparison of results of alcohol sclerotherapy with proposed MR imaging classification. Radiology 2002; 223:639-644.
11. Yakes WF, Rossi P, Odink H. Arteriovenous malformation management. Cardiovasc Intervent Radiol 1996; 19:65-71.
12. Dubois JL, Soulez G, Oliva VL, et al. Soft-tissue venous malformations in adult patients: imaging and therapeutic issues. Radiographics 2001; 21:1519-1531.
13. Lewin JS, Merkle EM, Duerk JL, et al. Low-flow vascular malformation in the head and neck: safety and feasibility of MR imaging-guided percutaneous sclerotherapy-preliminary experience with 14 procedures in three patients. Radiology 1999; 211:566-570.
14. Boll DT, Merkle EM, Lewin JS. Low-flow vascular malformations: MR-guided percutaneous sclerotherapy in qualitative and quantitative assessment of therapy and outcome. Radiology 2004; 233:376-384.
15. Hayashi N, Masumoto T, Okubo T, et al. Hemangiomas in the face and extremities: mr-guided sclerotherapy - optimization with monitoring of signal intensity changes in vivo. Radiology 2003; 226:567-572.
16. Runge VM. Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 2000; 12:205-213.
17. Matsumura K, Kiyota K, Inokuchi H, et al. A preliminary study of percutaneous ethanol injection therapy for hepatocellular carcinoma: evaluation of the ethanol diffusion area by the ethanol mixed with gadolinium. Nippon Igaku Hoshasen Gakkai Zasshi 1996; 56:517-519. Japanese.
18. Friedman MA, Wood BJ. Precipitation of gadolinium and ethanol during nerve block. J Vasc Interv Radiol 2003; 14:394.
19. Wysoki MG, White RI Jr. Crystallization when mixing contrast materials with ethanol for embolization of venous malformations. J Vasc Interv Radiol 2001; 12:264.
20. Greisberg JK, Wolf JM, Wyman J, et al. Gadolinium inhibits thymidine incorporation and induces apoptosis in chondrocytes. J Orthop Res 2001; 19:797-801.
21. Behra-Miellet J, Gressier B, Dine T, et al. Evaluation of the effects of Gd complexes used as magnetic resonance imaging contrast agents on superoxide dismutase: comparison of two methods. Inflammation 1999; 23:425-436.
22. Palasz A, Czekaj P. Toxicological and cytophysiological aspects of lanthanides action. Acta Biochim Pol 2000; 47:1107-1114.
23. Gibby WA, Gibby KA, Gibby WA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (Pro-Hance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 2004; 39:138-142.
24. Alexander A, Barrette T, Unger E. Magnetic resonance guidance of percutaneous ethanol injection in liver. Acad Radiol 1996; 3:18-25.
25. Shinmoto H, Mulkern RV, Oshio K, et al. MR appearance and spectral features of injected ethanol in the liver: implication for fast MR-guided percutaneous ethanol injection therapy. J Comput Assist Tomogr 1997; 21:82-88.
26. Domb BG, Khanna AJ, Mitchell SE, et al. Toe-walking attributable to venous malformation of the calf muscle. Clin Orthop 2004; 420:225-229.
27. Roberts DA, Rosen MA, Clark TWI, et al. Chemical-shift MR imaging of acetic acid during percutaneous chemical ablation therapy: preliminary work. J Vasc Interv Radiol 2002; 13:1055-1059.
28. Parodi JC, Ferreira LM. Gadolinium-based contrast: an alternative contrast agent for endovascular interventions. Ann Vasc Surg 2000; 14:480-483.
29. Hammer FD, Goffette PP, Malaise J, et al. Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography. Eur Radiol 1999; 9:128-136.
30. Blanche AFL, Tassart M, Deux JF, et al. Gadolinium-enhanced digital subtraction angiography of hemodialysis fistulas: a diagnostic and therapeutic approach. AJR Am J Roentgenol 2002; 179:1023-1028.
31. Kim MD, Kim H. Gadolinium dimeglumine as a contrast agent for digital subtraction angiography: in vitro Hounsfield unit measurement and clinical efficacy. Yonsei Med J 2003; 44:138-142.
32. Gückel C, Nidecker A. MR arthrographic findings in tenosynovitis of the long bicipital tendon of the shoulder. Skeletal Radiol 1998; 27:7-12.
33. Steinbach LS, Palmer WE, Schweitzer ME. MR arthrography. Radiographics 2002; 22:1223-1246.
34. Sequeiros RB, Klemola R, Ojala R, et al. Percutaneous MR-guided discography in a low-field system using optical instrument tracking: a feasibility study. J Magn Reson Imaging 2003; 17:214-219.
35. Solomon SB, Bohlman ME, Choti MA. Percutaneous gadolinium injection under MR guidance to mark target for CT-guided radiofrequency ablation. J Vasc Interv Radiol 2002; 13:419-421.
36. König CW, Schott UG, Pereira PL, et al. MR-guided lumbar sympathicolysis. Eur Radiol 2002; 12:1388-1393.
37. Ruehm SG, Schroeder T, Debatin JF. Interstitial MR lymphography with gadoterate meglumine: initial experience in humans. Radiology 2001; 220:816-821.
38. Rinck PA, Muller RN. Field strength and dose dependence of contrast enhancement by gadolinium-base MR contrast agents. Eur Radiol 1999; 9:998-1004.
39. Schwizer W, Fraser R, Maecke H, et al. Gd-DOTA as a gastrointestinal contrast agent for gastric emptying measurements with MRI. Magn Reson Med 1994; 31:388-393.
40. Look DC, Locker DR. Time saving in measurement of NMR and EPR relaxation times. Rev Sci Instr 1970; 41:250-251.